We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.34B
AUM Growth
-$262M
(-10%)
Cap. Flow
-$351M
Cap. Flow
% of AUM
-15.04%
Top 10 Holdings %
Top 10 Hldgs %
70.89%
Holding
36
New
3
Increased
7
Reduced
9
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$97.8M |
| 2 |
Viatris
VTRS
|
+$46.9M |
| 3 |
Puma Biotechnology
PBYI
|
+$36.2M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$35.3M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GHDX
Genomic Health, Inc.
GHDX
|
+$124M |
| 2 |
SHPG
Shire pic
SHPG
|
+$110M |
| 3 |
NUVA
NuVasive, Inc.
NUVA
|
+$62.5M |
| 4 |
Myriad Genetics
MYGN
|
+$56.1M |
| 5 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$53.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Surgery Partners
SGRY
$2.08B
| $2.23M | 0.1% |
135,084
| – | – |
|
27
CALL
Bristol-Myers Squibb
BMY
$133B
| – | – |
-2,000,000
| Closed | -$111M |
|
|
28
Myriad Genetics
MYGN
$291M
| – | – |
-1,500,000
| Closed | -$56.1M |
|
|
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-1,200,000
| Closed | -$62.5M |
|
|
CSII
30
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-1,647,677
| Closed | -$53.3M |
|
|
ENDP
31
DELISTED
Endo International plc
ENDP
| – | – |
-2,500,000
| Closed | -$23.6M |
|
|
WMGI
32
DELISTED
Wright Medical Group Inc
WMGI
| – | – |
-1,250,000
| Closed | -$32.5M |
|
|
MNK
33
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-1,900,000
| Closed | -$35.5M |
|
|
GHDX
34
DELISTED
Genomic Health, Inc.
GHDX
| – | – |
-2,458,100
| Closed | -$124M |
|
|
CELG
35
CALL
DELISTED
Celgene Corp
CELG
| – | – |
-1,000,000
| Closed | -$79.4M |
|
|
SHPG
36
DELISTED
Shire pic
SHPG
| – | – |
-650,000
| Closed | -$110M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Camber Capital Management held 36 positions worth $2.34B, down 10% from $2.6B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Camber Capital Management withdrew a net $351M in Q3 2018, closing 10 positions and reducing 9 holdings. Its most notable exit was Genomic Health, Inc., an estimated $124M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier.
Against the trend, Camber Capital Management opened a new position in McKesson worth $99.5M.
- Camber Capital Management's largest Q3 2018 buy was McKesson: 750,000 shares worth $99.5M.
- Camber Capital Management added most to Viatris in Q3 2018, an estimated $46.9M increase.
- Camber Capital Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $51.6M.
- Camber Capital Management fully exited Genomic Health, Inc. in Q3 2018, selling an estimated $124M.
- Camber Capital Management's ten largest holdings make up 71% of its $2.34B portfolio in Q3 2018.
- Camber Capital Management opened 3 new positions and closed 10 in Q3 2018.
- Camber Capital Management's portfolio value fell 10% quarter-over-quarter to $2.34B.
Based on Camber Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.